Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lynk Pharma to Start Trials of Novel Therapy for IBD

publication date: Jun 25, 2021

Hangzhou Lynk Pharma has been OK'd to start clinical trials of a novel Class I drug in patients with inflammatory bowel disease (IBD). LNK01003 is a kinase inhibitor that offers low systemic exposure and high intestinal exposure, lowering potential toxicity caused by immune system suppression. Lynk did not give any details about the candidate's mechanism. LNK01003 is the third Lynk candidate approved for clinical trials. Founded in 2018, Lynk discovers and develops innovative drugs to treat cancer, as well as immune and inflammatory diseases. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here